TNF, but not IL-6 and IL-17, is crucial for the development of T cell-independent psoriasis-like dermatitis in Il1rn-/- mice

Journal of Immunology

Volumn 185, Issue 3, 2010, Pages 1887-1893

  Nakajima, Akiko ^a,d   Matsuki, Taizo ^a,e   Komine, Mayumi ^b,f   Asahina, Akihiko ^b,g   Horai, Reiko ^a,h   Nakae, Susumu ^a   Ishigame, Harumichi ^a,i   Kakuta, Shigeru ^a   Saijo, Shinobu ^a   Iwakura, Yoichiro ^a,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d Maruho Co   (Japan)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f JICHI MEDICAL UNIVERSITY   (Japan)

^g SAGAMIHARA NATIONAL HOSPITAL   (Japan)

^h NATIONAL EYE INSTITUTE   (United States)

ⁱ YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 17; INTERLEUKIN 6; TUMOR NECROSIS FACTOR; AUTACOID; IL1RN PROTEIN, MOUSE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTITIS; ARTHRITIS; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DERMATITIS; DISEASE COURSE; GENE TRANSFER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; SKIN CELL; T LYMPHOCYTE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; COMPARATIVE STUDY; CONTACT DERMATITIS; FEMALE; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; SKIN; T LYMPHOCYTE SUBPOPULATION; TRANSPLANTATION;

ANIMALS; DERMATITIS, CONTACT; FEMALE; INFLAMMATION MEDIATORS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-17; INTERLEUKIN-6; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, SCID; PSORIASIS; SKIN; T-LYMPHOCYTE SUBSETS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956404314     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001227     Document Type: Article

References (60)

1. Nickoloff, B. J., and F. O. Nestle. 2004. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J. Clin. Invest. 113: 1664-1675.
2. Lowes, M. A., A. M. Bowcock, and J. G. Krueger. 2007. Pathogenesis and therapy of psoriasis. Nature 445: 866-873.
3. Ferenczi, K., L. Burack, M. Pope, J. G. Krueger, and L. M. Austin. 2000. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J. Autoimmun. 14: 63-78.
4. Boyman, O., H. P. Hefti, C. Conrad, B. J. Nickoloff, M. Suter, and F. O. Nestle. 2004. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J. Exp. Med. 199: 731-736.
5. Wrone-Smith, T., and B. J. Nickoloff. 1996. Dermal injection of immunocytes induces psoriasis. J. Clin. Invest. 98: 1878-1887.
6. Di Cesare, A., P. Di Meglio, and F. O. Nestle. 2009. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J. Invest. Dermatol. 129: 1339-1350.
7. Groves, R. W., L. Sherman, H. Mizutani, S. K. Dower, and T. S. Kupper. 1994. Detection of interleukin-1 receptors in human epidermis. Induction of the type II receptor after organ culture and in psoriasis. Am. J. Pathol. 145: 1048-1056.
8. Hammerberg, C., W. P. Arend, G. J. Fisher, L. S. Chan, A. E. Berger, J. S. Haskill, J. J. Voorhees, and K. D. Cooper. 1992. Interleukin-1 receptor antagonist in normal and psoriatic epidermis. J. Clin. Invest. 90: 571-583.
9. Hedrick, M. N., A. S. Lonsdorf, A. K. Shirakawa, C. C. Richard Lee, F. Liao, S. P. Singh, H. H. Zhang, A. Grinberg, P. E. Love, S. T. Hwang, and J. M. Farber. 2009. CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. J. Clin. Invest. 119: 2317-2329.
10. Lowes, M. A., T. Kikuchi, J. Fuentes-Duculan, I. Cardinale, L. C. Zaba, A. S. Haider, E. P. Bowman, and J. G. Krueger. 2008. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. Invest. Dermatol. 128: 1207-1211.
11. Piskin, G., R. M. Sylva-Steenland, J. D. Bos, and M. B. Teunissen. 2006. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J. Immunol. 176: 1908-1915.
12. van Beelen, A. J., M. B. Teunissen, M. L. Kapsenberg, and E. C. de Jong. 2007. Interleukin-17 in inflammatory skin disorders. Curr. Opin. Allergy Clin. Immunol. 7: 374-381.
13. Wilson, N. J., K. Boniface, J. R. Chan, B. S. McKenzie, W. M. Blumenschein, J. D. Mattson, B. Basham, K. Smith, T. Chen, F. Morel, et al. 2007. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 8: 950-957.
14. Zaba, L. C., I. Cardinale, P. Gilleaudeau, M. Sullivan-Whalen, M. Suárez-Fariñas, M. Suárez Fariñas, J. Fuentes-Duculan, I. Novitskaya, A. Khatcherian, M. J. Bluth, et al. 2007. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. [Published erratum appears in 2008. J. Exp. Med. 205: 1941.] J. Exp. Med. 204: 3183-3194.
15. Capon, F., P. Di Meglio, J. Szaub, N. J. Prescott, C. Dunster, L. Baumber, K. Timms, A. Gutin, V. Abkevic, A. D. Burden, et al. 2007. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum. Genet. 122: 201-206.
16. Cargill, M., S. J. Schrodi, M. Chang, V. E. Garcia, R. Brandon, K. P. Callis, N. Matsunami, K. G. Ardlie, D. Civello, J. J. Catanese, et al. 2007. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 80: 273-290.
17. Nair, R. P., K. C. Duffin, C. Helms, J. Ding, P. E. Stuart, D. Goldgar, J. E. Gudjonsson, Y. Li, T. Tejasvi, B. J. Feng, et al, and Collaborative Association Study of Psoriasis. 2009. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat. Genet. 41: 199-204.
18. Horai, R., S. Saijo, H. Tanioka, S. Nakae, K. Sudo, A. Okahara, T. Ikuse, M. Asano, and Y. Iwakura. 2000. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. 191: 313-320.
19. Nicklin, M. J., D. E. Hughes, J. L. Barton, J. M. Ure, and G. W. Duff. 2000. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J. Exp. Med. 191: 303-312.
20. Matsuki, T., K. Isoda, R. Horai, A. Nakajima, Y. Aizawa, K. Suzuki, F. Ohsuzu, and Y. Iwakura. 2005. Involvement of tumor necrosis factor-alpha in the development of T cell-dependent aortitis in interleukin-1 receptor antagonist-deficient mice. Circulation 112: 1323-1331. (Pubitemid 41266728)
21. Shepherd, J., M. C. Little, and M. J. Nicklin. 2004. Psoriasis-like cutaneous inflammation in mice lacking interleukin-1 receptor antagonist. J. Invest. Dermatol. 122: 665-669.
22. Nicklin, M., and J. Stepherd. 2003. IL-1 receptor antagonist-deficient mice. In Cytokine knockouts. G. Fantuzzi, ed. Humana Press, Totowa, NJ, p. 111-134.
23. Gudjonsson, J. E., A. Johnston, M. Dyson, H. Valdimarsson, and J. T. Elder. 2007. Mouse models of psoriasis. J. Invest. Dermatol. 127: 1292-1308.
24. Horai, R., A. Nakajima, K. Habiro, M. Kotani, S. Nakae, T. Matsuki, A. Nambu, S. Saijo, H. Kotaki, K. Sudo, et al. 2004. TNF-α is crucial for the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice. J. Clin. Invest. 114: 1603-1611.
25. Nakae, S., A. Nambu, K. Sudo, and Y. Iwakura. 2003. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 171: 6173-6177. (Pubitemid 37467240)
26. Nakae, S., S. Saijo, R. Horai, K. Sudo, S. Mori, and Y. Iwakura. 2003. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc. Natl. Acad. Sci. USA 100: 5986-5990.
27. Horai, R., M. Asano, K. Sudo, H. Kanuka, M. Suzuki, M. Nishihara, M. Takahashi, and Y. Iwakura. 1998. Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. J. Exp. Med. 187: 1463-1475.
28. Taniguchi, T., M. Takata, A. Ikeda, E. Momotani, and K. Sekikawa. 1997. Failure of germinal center formation and impairment of response to endotoxin in tumor necrosis factor alpha-deficient mice. Lab. Invest. 77: 647-658.
29. Kopf, M., H. Baumann, G. Freer, M. Freudenberg, M. Lamers, T. Kishimoto, R. Zinkernagel, H. Bluethmann, and G. Köhler. 1994. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368: 339-342. (Pubitemid 24104268)
30. Nakae, S., Y. Komiyama, A. Nambu, K. Sudo, M. Iwase, I. Homma, K. Sekikawa, M. Asano, and Y. Iwakura. 2002. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 17: 375-387.
31. Gillitzer, R., U. Ritter, U. Spandau, M. Goebeler, and E. B. Bröcker. 1996. Differential expression of GRO-alpha and IL-8 mRNA in psoriasis: a model for neutrophil migration and accumulation in vivo. J. Invest. Dermatol. 107: 778-782.
32. Goebeler, M., A. Toksoy, U. Spandau, E. Engelhardt, E. B. Bröcker, and R. Gillitzer. 1998. The C-X-C chemokine Mig is highly expressed in the papillae of psoriatic lesions. J. Pathol. 184: 89-95.
33. Schmuth, M., S. Neyer, C. Rainer, A. Grassegger, P. Fritsch, N. Romani, and C. Heufler. 2002. Expression of the C-C chemokine MIP-3 alpha/CCL20 in human epidermis with impaired permeability barrier function. Exp. Dermatol. 11: 135-142.
34. Bonifati, C., and F. Ameglio. 1999. Cytokines in psoriasis. Int. J. Dermatol. 38: 241-251.
35. Nakae, S., Y. Komiyama, S. Narumi, K. Sudo, R. Horai, Y. Tagawa, K. Sekikawa, K. Matsushima, M. Asano, and Y. Iwakura. 2003. IL-1-induced tumor necrosis factor-alpha elicits inflammatory cell infiltration in the skin by inducing IFN-γ-inducible protein 10 in the elicitation phase of the contact hypersensitivity response. Int. Immunol. 15: 251-260.
36. Ishigame, H., A. Nakajima, S. Saijo, Y. Komiyama, A. Nambu, T. Matsuki, S. Nakae, R. Horai, S. Kakuta, and Y. Iwakura. 2006. The role of TNFalpha and IL-17 in the development of excess IL-1 signaling-induced inflammatory diseases in IL-1 receptor antagonist-deficient mice. Ernst Schering Res. Found. Workshop 56: 129-153.
37. Feldmann, M., and R. N. Maini. 2001. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 19: 163-196.
38. Keffer, J., L. Probert, H. Cazlaris, S. Georgopoulos, E. Kaslaris, D. Kioussis, and G. Kollias. 1991. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10: 4025-4031.
39. Stalder, A. K., M. J. Carson, A. Pagenstecher, V. C. Asensio, C. Kincaid, M. Benedict, H. C. Powell, E. Masliah, and I. L. Campbell. 1998. Late-onset chronic inflammatory encephalopathy in immune-competent and severe combined immune-deficient (SCID) mice with astrocyte-targeted expression of tumor necrosis factor. Am. J. Pathol. 153: 767-783.
40. Chaudhari, U., P. Romano, L. D. Mulcahy, L. T. Dooley, D. G. Baker, and A. B. Gottlieb. 2001. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357: 1842-1847.
41. Mease, P. J., B. S. Goffe, J. Metz, A. VanderStoep, B. Finck, and D. J. Burge. 2000. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356: 385-390.
42. Feldmann, M., F. M. Brennan, and R. N. Maini. 1996. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14: 397-440.
43. Lee, E., W. L. Trepicchio, J. L. Oestreicher, D. Pittman, F. Wang, F. Chamian, M. Dhodapkar, and J. G. Krueger. 2004. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199: 125-130.
44. Chan, J. R., W. Blumenschein, E. Murphy, C. Diveu, M. Wiekowski, S. Abbondanzo, L. Lucian, R. Geissler, S. Brodie, A. B. Kimball, et al. 2006. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J. Exp. Med. 203: 2577-2587.
45. Krueger, G. G., R. G. Langley, C. Leonardi, N. Yeilding, C. Guzzo, Y. Wang, L. T. Dooley, M. Lebwohl, and CNTO 1275 Psoriasis Study Group. 2007. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356: 580-592.
46. Leonardi, C. L., A. B. Kimball, K. A. Papp, N. Yeilding, C. Guzzo, Y. Wang, S. Li, L. T. Dooley, K. B. Gordon, and PHOENIX 1 study investigators. 2008. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371: 1665-1674.
47. Diveu, C., M. J. McGeachy, and D. J. Cua. 2008. Cytokines that regulate autoimmunity. Curr. Opin. Immunol. 20: 663-668.
48. Steinman, L. 2010. Mixed results with modulation of TH-17 cells in human autoimmune diseases. Nat. Immunol. 11: 41-44.
49. Iwakura, Y., S. Nakae, S. Saijo, and H. Ishigame. 2008. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol. Rev. 226: 57-79.
50. Alonzi, T., E. Fattori, D. Lazzaro, P. Costa, L. Probert, G. Kollias, F. De Benedetti, V. Poli, and G. Ciliberto. 1998. Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. 187: 461-468.
51. Hata, H., N. Sakaguchi, H. Yoshitomi, Y. Iwakura, K. Sekikawa, Y. Azuma, C. Kanai, E. Moriizumi, T. Nomura, T. Nakamura, and S. Sakaguchi. 2004. Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J. Clin. Invest. 114: 582-588.
52. Samoilova, E. B., J. L. Horton, B. Hilliard, T. S. Liu, and Y. Chen. 1998. IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J. Immunol. 161: 6480-6486.
53. Camargo, C. A., Jr., J. F. Madden, W. Gao, R. S. Selvan, and P. A. Clavien. 1997. Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent. Hepatology 26: 1513-1520.
54. Kagari, T., H. Doi, and T. Shimozato. 2002. The importance of IL-1 beta and TNF-alpha, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. J. Immunol. 169: 1459-1466.
55. Jacobs, J. P., H. J. Wu, C. Benoist, and D. Mathis. 2009. IL-17-producing T cells can augment autoantibody-induced arthritis. Proc. Natl. Acad. Sci. USA 106: 21789-21794.
56. Ji, H., A. Pettit, K. Ohmura, A. Ortiz-Lopez, V. Duchatelle, C. Degott, E. Gravallese, D. Mathis, and C. Benoist. 2002. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J. Exp. Med. 196: 77-85.
57. Sano, S., K. S. Chan, S. Carbajal, J. Clifford, M. Peavey, K. Kiguchi, S. Itami, B. J. Nickoloff, and J. DiGiovanni. 2005. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med. 11: 43-49.
58. Pasparakis, M., G. Courtois, M. Hafner, M. Schmidt-Supprian, A. Nenci, A. Toksoy, M. Krampert, M. Goebeler, R. Gillitzer, A. Israel, et al. 2002. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature 417: 861-866.
59. Zenz, R., R. Eferl, L. Kenner, L. Florin, L. Hummerich, D. Mehic, H. Scheuch, P. Angel, E. Tschachler, and E. F. Wagner. 2005. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 437: 369-375.
60. Angel, P., and A. Szabowski. 2002. Function of AP-1 target genes in mesenchymal-epithelial cross-talk in skin. Biochem. Pharmacol. 64: 949-956.